

Table S1 Virological testing methods and proportions (n=234)

Target virus	Method	Kit/platform	Gene target	No. of tests	Notes
H1N1	Real-time RT-PCR	CDC-recommended InfA/H1 primers/probe	H1 gene	234 (100%)	Antigen tests not used
SARS-CoV-2	Real-time RT-PCR	NMPA-emergency-approved kit	ORF1ab + N genes	234 (100%)	Antigen tests not used
Coinfection	Dual RT-PCR	Combined above two kits	H1 + ORF1ab/N	64 (27.4%)	Both viruses detected within 7 days

Throughout the study period, no influenza or SARS-CoV-2 antigen rapid tests were employed, eliminating the risk of false-positives due to antigen cross-reactivity. All assays were performed in the hospital's central laboratory under strict quality-control protocols.